Kyowa Kirin Co., Ltd.

DB:KY4 Stock Report

Market Cap: €7.3b

Kyowa Kirin Past Earnings Performance

Past criteria checks 5/6

Kyowa Kirin has been growing earnings at an average annual rate of 15.6%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 9.2% per year. Kyowa Kirin's return on equity is 10%, and it has net margins of 16.7%.

Key information

15.6%

Earnings growth rate

15.7%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate9.2%
Return on equity10.0%
Net Margin16.7%
Next Earnings Update06 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Kyowa Kirin makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:KY4 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24498,97883,535167,37895,225
30 Jun 24475,99897,319163,87987,697
31 Mar 24454,26783,060161,46378,803
31 Dec 23442,23381,188163,07872,106
30 Sep 23420,64957,915158,13869,927
30 Jun 23412,30940,202162,07768,639
31 Mar 23404,15550,295161,79665,906
31 Dec 22398,37153,573166,18562,896
30 Sep 22382,05268,651148,26561,591
30 Jun 22372,49662,292144,30759,093
31 Mar 22358,88255,464139,53959,095
31 Dec 21352,24652,347135,10557,679
30 Sep 21338,31742,446132,49555,518
30 Jun 21325,55444,301125,53754,739
31 Mar 21322,17446,106118,47452,705
31 Dec 20318,35247,027116,52552,312
30 Sep 20314,36748,255110,49852,674
30 Jun 20312,22346,819109,17252,702
31 Mar 20307,27842,212109,27553,393
31 Dec 19305,82037,674106,24553,511
30 Sep 19374,26738,519121,87154,203
30 Jun 19325,82738,796107,90950,395
31 Mar 19337,64541,713108,97249,594
31 Dec 18346,53154,414110,28348,591
30 Sep 18292,66265,95395,51245,242
30 Jun 18349,81563,500108,09347,611
31 Mar 18347,16656,420106,32148,301
31 Dec 17353,38042,899104,60849,155
30 Sep 17343,69721,949101,40751,146
30 Jun 17344,64821,576100,09051,138
31 Mar 17345,48519,754100,66651,855
31 Dec 16343,01918,669100,62153,792
30 Sep 16349,13420,199103,03854,156
30 Jun 16359,53531,014104,85254,670
31 Mar 16363,18732,566104,81853,096
31 Dec 15364,31629,774105,70251,518
30 Sep 15367,45329,906104,17451,343
30 Jun 15350,38416,236103,16349,892
31 Mar 15336,96514,173101,05449,442
31 Dec 14333,44615,89899,39647,667
30 Sep 14327,44418,791100,05045,405
30 Jun 14332,80321,58598,60344,541
31 Mar 14340,09026,01085,67453,986

Quality Earnings: KY4 has high quality earnings.

Growing Profit Margin: KY4's current net profit margins (16.7%) are higher than last year (13.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: KY4's earnings have grown by 15.6% per year over the past 5 years.

Accelerating Growth: KY4's earnings growth over the past year (44.2%) exceeds its 5-year average (15.6% per year).

Earnings vs Industry: KY4 earnings growth over the past year (44.2%) exceeded the Pharmaceuticals industry 25.4%.

Return on Equity

High ROE: KY4's Return on Equity (10%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/15 06:02
End of Day Share Price 2025/01/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kyowa Kirin Co., Ltd. is covered by 23 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Toshiro YoshinagaAizawa Securities Co. Ltd.
Atsushi SekiBarclays
Koichi MameganoBofA Global Research